NCI-H1299Homo sapiens (Human)Cancer cell line
Also known as: NCIH1299, H-1299, H1299, HI299 (Occasionally.)
Quick Overview
Human non-small cell lung cancer cell line with mesenchymal characteristics
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0060 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lymph node[UBERON:UBERON_0000029] |
Donor Information
| Age | 43 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Lung large cell carcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Large Cell Lung Carcinoma |
| OncoTree Code | LCLC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000510_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | NRAS | p.Gln61Lys (c.181C>A) | Unspecified | Acquired during resistance selection process | PubMed=26214590 |
| Gene deletion | TP53 | - | Homozygous | 2 out of 3 copies | from parent cell line HL-60 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Chemical proteomics reveals interactors of the alarmone diadenosine triphosphate in the cancer cell line H1299.
Marx A.
J. Pept. Sci. 29:e3458.1-e3458.10(2023).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
High-throughput sequencing for species authentication and contamination detection of 63 cell lines.
Moniwa M.
Sci. Rep. 11:21657-21657(2021).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.
Minna J.D., Wistuba I.I., Pertsemlidis A.
Oncotarget 9:29601-29618(2018).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.
Hanash S.M., Ostrin E.J.
Proc. Natl. Acad. Sci. U.S.A. 113:E1555-E1564(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Human biosample authentication using the high-throughput, cost-effective SNPtrace(TM) system.
Bourgon R., Neve R.M.
PLoS ONE 10:E0116218-E0116218(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Brain tumor cell line authentication, an efficient alternative to capillary electrophoresis by using a microfluidics-based system.
An Q., Fillmore H.L., Vouri M., Pilkington G.J.
Neuro-oncol. 16:265-273(2014).
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Heymach J.V.
Cancer Discov. 2:798-811(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Lung cancer cell lines as tools for biomedical discovery and research.
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
J. Natl. Cancer Inst. 102:1310-1321(2010).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer.
Cigudosa J.C., Lazo P.A., Sanchez-Cespedes M.
Hum. Mol. Genet. 18:1343-1352(2009).
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Cell 131:1190-1203(2007).
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Takada M., Fukuoka M., Nakagawa K.
Cancer Res. 67:2046-2053(2007).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Oncogene 19:4632-4639(2000).
NCI-Navy Medical Oncology Branch cell line data base.";
Carney D.N., Minna J.D., Mulshine J.L.
J. Cell. Biochem. Suppl. 24:32-91(1996).
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
Linnoila R.I.
Oncogene 7:743-749(1992).
Neuromedin B is present in lung cancer cell lines.";
Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.
Cancer Res. 52:2732s-2736s(1992).
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Gazdar A.F.
Oncogene 7:171-180(1992).